171 related articles for article (PubMed ID: 27299522)
1. Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink.
Matthews A; Langan SM; Douglas IJ; Smeeth L; Bhaskaran K
PLoS Med; 2016 Jun; 13(6):e1002037. PubMed ID: 27299522
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.
Lian Y; Yin H; Pollak MN; Carrier S; Platt RW; Suissa S; Azoulay L
Eur Urol; 2016 Nov; 70(5):808-815. PubMed ID: 27178449
[TBL] [Abstract][Full Text] [Related]
3. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis.
Tang H; Wu W; Fu S; Zhai S; Song Y; Han J
J Am Acad Dermatol; 2017 Sep; 77(3):480-488.e9. PubMed ID: 28728871
[TBL] [Abstract][Full Text] [Related]
5. Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis.
Feng S; Zhou L; Liu Q; He Q; Liao B; Wei X; Li H; Wang K; Zhu Y
Medicine (Baltimore); 2018 Jan; 97(3):e9601. PubMed ID: 29504984
[TBL] [Abstract][Full Text] [Related]
6. Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta-analysis.
Deng T; Duan X; Liu B; Lan Y; Cai C; Zhang T; Zhu W; Mai Z; Wu W; Zeng G
Neoplasma; 2018; 65(2):216-221. PubMed ID: 29534582
[TBL] [Abstract][Full Text] [Related]
7. Use of Phosphodiesterase 5 Inhibitors Is Associated With Lower Risk of Colorectal Cancer in Men With Benign Colorectal Neoplasms.
Huang W; Sundquist J; Sundquist K; Ji J
Gastroenterology; 2019 Sep; 157(3):672-681.e4. PubMed ID: 31103628
[TBL] [Abstract][Full Text] [Related]
8. Hormone replacement therapy and the risk of melanoma in post-menopausal women.
Hicks BM; Kristensen KB; Pedersen SA; Hölmich LR; Pottegård A
Hum Reprod; 2019 Dec; 34(12):2418-2429. PubMed ID: 31803923
[TBL] [Abstract][Full Text] [Related]
9. Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review.
Wang J; Shen Y; Wang J; Xue Y; Liao L; Thapa S; Ji K
Oncotarget; 2017 Jul; 8(28):46461-46467. PubMed ID: 28515348
[TBL] [Abstract][Full Text] [Related]
10. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Shkolyar E; Li S; Tang J; Eisenberg ML
J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
[TBL] [Abstract][Full Text] [Related]
11. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study.
Li WQ; Qureshi AA; Robinson KC; Han J
JAMA Intern Med; 2014 Jun; 174(6):964-70. PubMed ID: 24710960
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase 5 Inhibitor Use and Risk of Conventional and Serrated Precursors of Colorectal Cancer.
Zhang Y; Lo CH; Giovannucci EL
Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):419-421. PubMed ID: 33355205
[TBL] [Abstract][Full Text] [Related]
13. No association between use of phosphodiesterase 5 inhibitors and colorectal cancer in men with erectile dysfunction.
Cea Soriano L; García Rodríguez LA
Pharmacoepidemiol Drug Saf; 2020 May; 29(5):605-608. PubMed ID: 32267029
[TBL] [Abstract][Full Text] [Related]
14. Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer.
Rouette J; Yin H; Pottegård A; Nirantharakumar K; Azoulay L
Drug Saf; 2021 Feb; 44(2):245-254. PubMed ID: 33104975
[TBL] [Abstract][Full Text] [Related]
15. The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review.
Cilio S; Briatico G; Brancaccio G; Capone F; Ferro M; Imbimbo C; Salonia A; Argenziano G; Crocetto F
J Basic Clin Physiol Pharmacol; 2023 Nov; 34(6):691-697. PubMed ID: 37982667
[TBL] [Abstract][Full Text] [Related]
16. Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: Population-based cohort study.
Liu W; Antonelli PJ; Dahm P; Gerhard T; Delaney JAC; Segal R; Crystal S; Winterstein AG
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):587-595. PubMed ID: 29512263
[TBL] [Abstract][Full Text] [Related]
17. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
Kell PD; Hvidsten K; Morant SV; Harnett JP; Bridge S
BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
[TBL] [Abstract][Full Text] [Related]
18. Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma.
Pottegård A; Schmidt SA; Olesen AB; Achacoso N; Van Den Eeden SK; Hallas J; Sørensen HT; Friis S; Habel LA
Br J Cancer; 2016 Sep; 115(7):895-900. PubMed ID: 27529513
[TBL] [Abstract][Full Text] [Related]
19. Association Between Health Maintenance Practices and Skin Cancer Risk as a Possible Source of Detection Bias.
Drucker AM; Li WQ; Savitz DA; Weinstock MA; Han J; Li T; Qureshi AA; Cho E
JAMA Dermatol; 2019 Mar; 155(3):353-357. PubMed ID: 30586131
[TBL] [Abstract][Full Text] [Related]
20. Electronically delivered interventions to reduce antibiotic prescribing for respiratory infections in primary care: cluster RCT using electronic health records and cohort study.
Gulliford MC; Juszczyk D; Prevost AT; Soames J; McDermott L; Sultana K; Wright M; Fox R; Hay AD; Little P; Moore M; Yardley L; Ashworth M; Charlton J
Health Technol Assess; 2019 Mar; 23(11):1-70. PubMed ID: 30900550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
